Perceptic: The $12M AI Startup from Ex-Palantir Execs Building Pharma's Missing Operating System

The $12 Million Seed Round

The funding was led by Accel, with participation from Air Street Capital and Elder Gull . The valuation was not disclosed . Accel partner Sonali De Rycker pointed to two factors that convinced the firm: the platform's ability to span the entire drug lifecycle rather than a single step, and the fact that Perceptic had already progressed beyond pilots to paid production deployments before its public launch .

The Platform: Three Modules Across the Drug Lifecycle

Perceptic describes its platform as an "intelligence layer" that sits above existing data, tools, and workflows—connecting siloed departments without forcing companies to rip out their infrastructure . It is infrastructure- and model-agnostic, meaning customers can bring their own data, compute, and AI models . The system is organized into three named products:

Scout — External Asset Intelligence

Scout is designed for scouting and triaging external drug assets, such as licensing candidates and competitive programs. Perceptic claims it compresses scientific due diligence from weeks to approximately one hour and scales asset screening from hundreds per week to thousands in minutes .

PercepticOS — Internal Decision Intelligence

This module functions as a hypothesis-testing and decision-support layer. Teams use it to test scientific hypotheses, compare internal data against external benchmarks, and select clinical trial indications . The goal is to accelerate go/no-go decisions with better cross-functional data visibility.

Atlas — Clinical Data Foundation

Atlas harmonizes internal and external clinical trial data into a unified foundation. Live deployments have already produced a 50-fold increase in clinical data extractions, a figure that signals significant automation of manual data work inside trial analytics .

Early Traction and Market Position

Unusually for a seed-stage startup, Perceptic opened its public launch with paid production deployments across multiple top-20 pharmaceutical companies. The only publicly named customer is CSL, the Australian-headquartered global biotechnology company .

The core pitch is that the platform "follows the drug, not the department"—a deliberate contrast to the fragmented tooling landscape that dominates pharma R&D today . Rather than selling a tool for medicinal chemists, another for clinical operations, and another for business development, Perceptic aims to be the cross-functional system that connects them all.

This unified approach comes directly from the founders' experience at Palantir, where they learned that AI in regulated industries fails when it is bolted onto isolated workflows rather than embedded into the decision-making fabric of the organization .